CA-ENCHROMA-INC
EnChroma, Inc. – creators of glasses for color blindness – today announced the launch of International Color Blindness Awareness Month. During the entire month of September, EnChroma and over 50 museums, libraries, school districts, state and federal parks, universities, tourism agencies, and Lions and Kiwanis Clubs will make social media posts and publish other communications designed to educate their members, students, communities and/or followers about Color Vision Deficiency (CVD, or “color blindness”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005741/en/
Image courtesy of EnChroma @enchroma
“We are pleased that so many esteemed institutions have joined EnChroma to promote International Color Blindness Month to educate the world about the impact color vision deficiency has on people at work, in school, and in fully appreciating art or the colors of nature,” said Erik Ritchie, CEO of EnChroma. “More awareness will result in fewer daily frustrations for color blind people and more accessibility.”
Color blindness affects one in 12 men (8%) and one in 200 women (.5%); 350 million people worldwide. While people with normal color vision see over one million shades of color, those with Color Vision Deficiency only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red can appear brown. Click here for images depicting color blindness.
The 50+ organizations supporting International Color Blindness Month include:
• Georgia O'Keeffe Museum, NM |
• Boston University, MA |
• Faber-Castell, Germany |
• North Carolina State University, NC |
• Birmingham Museum of Art, AL |
• Anythink Libraries, CO |
• Museum of Contemporary Art Denver |
• Penn State University, Forensic Science Dept., PA |
|
• J.N. "Ding" Darling National Wildlife Refuge, FL |
• Fondazione Paolina Brugnatelli, Milan, Italy |
|
• Lions Club, District L, NC |
• Clinton-Macomb Public Library, MI |
• Cantigny Park, IL |
• Nelson-Atkins Museum of Art, MO |
• School District of New London, WI |
• Nahant Public Library, MA |
• Johnson County Public Library, IN |
• Dallas Museum of Art, TX |
• Lions Club, Adams, MN |
• RISD, Museum of Art, Rhode Island School of Design, RI |
• St. Johns County Public Libraries, FL |
|
• Alfred University, NY |
• Museum of Fine Arts, St. Petersburg, FL |
• i.d.e.a. Museum, AZ |
• Central High School (D301), IL |
• Kiwanis Club of Findlay, OH |
• Shelburne Museum, VT |
• Glen Ridge Public Library, NJ |
• Lions Club, District I, NC |
• Downers Grove Public Library, IL |
• National Museum of Wildlife Art, WY |
• Motlow State Community College, TN |
• Mulvane Art Museum, KS |
• Lions Club, District S, NC |
• Albrecht-Kemper Museum of Art, MO |
• Spiva Center for the Arts, MO |
• Eye See Color Project, FL |
• Helsingin Optiikka Oy, Finland |
• Plainfield Area Public Library, IN |
• Evansville Vanderburgh Public Library, IN |
•Technology Aids for the Blind & Visually Impaired, NC |
|
• Lions Club, District O, NC |
• Unique Optiek BV, The Netherlands |
• Lions Club, District N, NC |
• Carolyn Campagna Kleefeld Contemporary Art Museum, CA |
• Jonathan Jones Color Blind Fund, AZ |
|
EnChroma encourages other organizations and individuals to promote color blindness awareness anytime in September by posting to social media, websites and other forums using any of the templates located here, and/or images showing the color blind view of various settings here.
EnChroma Color Accessibility Program
EnChroma continues to lead in advocating for “color accessibility” through its EnChroma Color Accessibility Program, in which over 150 organizations participate. The program helps public venues such as schools, state parks, libraries, museums, tourism bureaus, resorts and other organizations loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the color blind.
Through the program, EnChroma donates a pair of glasses to an organization for every pair it purchases. Materials to educate teachers, parents, employers and others about color blindness, and how to support color blind students, children, employees and visitors, are also provided. EnChroma encourages schools to easily and quickly test all students for color blindness using its free online color vision test. Email accessibility@enchroma.com to learn about the program.
EnChroma’s patented lens technology helps people with red-green color blindness see an expanded range of colors and see them more vibrantly, clearly and distinctly. Studies by world-renowned color vision scientists at the University of California, Davis and France’s INSERM Stem Cell and Brain Research Institute, and the University of the Incarnate Word, have demonstrated the effectiveness of EnChroma glasses.
Story Assets for Media
Visit our Media Kit to download user videos, photos of EnChroma glasses and b-roll.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
